Kymera Investor Day Presentation Deck
TARGET
SELECTION
Unique approach
focused on
undrugged or not
fully drugged
targets with
broad indication
potentials
KYMERA
Kymera's Differentiated Approach to TPD
TPD
"FIRSTS"
PLATFORM
Significantly
differentiated
investments
Tissue-
selective
E3 Ligases
Enabling a
whole new
generation
of clinical
programs
©2021 KYMERA THERAPEUTICS, INC.
New
Molecular
Glue
Approach
Novel
strategy to
address
undrugged/
un-ligandable
targets
Innovative clinical
trial designs for
degrader
development
Absolute IRAK4 Levels
Mean (SE) [fmol/ug Protein]
2.0
1.5
1.0
0.5
CLINICAL
0.0
1 2 3 4
Day
14
Kymera has
accomplished several
"firsts" in TPD
% Remaining on Study
100
KYMERA R&D DAY - December 16th, 2021
40
0
7
14
21
42
Day Post Tumor Implant
KT-474/
IRAK4
FIRST
randomized,
placebo-
controlled
trial in
healthy
volunteers
28
35
49
56
63
KT-333/
STAT3
FIRST
Hetero-
bifunctional
degrader
against an
undrugged
transcription
factor in clinic
INNOVATION
Serious
commitment to
constant evolution
of our science
G
PAGE 13View entire presentation